New research reveals teclistamab and daratumumab significantly enhance progression-free survival in multiple myeloma, reshaping treatment standards. Maria-Victoria Mateos, MD, PhD, closed out the late ...

Histopathological image of multiple myoloma. Smear preparation of bone marrow aspirate stained with May-Grünwald-Giemsa procedure. It doest not represent a histopathologic image but essentially helps ...

In a phase 1–2 trial, teclistamab, a bispecific antibody targeting CD3 on T-cell surfaces and B-cell maturation antigen on myeloma cells, showed durable responses in heavily pretreated patients with ...

Light chain multiple myeloma is a subtype of multiple myeloma, a cancer of the plasma cells in bone marrow. Symptoms can include bone pain, fatigue, infections, swelling, and more. Multiple myeloma is ...

A quadruplet regimen is now the preferred first-line treatment for multiple myeloma in both transplant-eligible and ineligible patients, reflecting a major guideline update. New regimens for ...

Daratumumab, a monoclonal antibody targeting CD38, has been approved for use with standard myeloma regimens. An evaluation of subcutaneous daratumumab combined with bortezomib, lenalidomide, and ...

The types of active multiple myeloma are categorized by the overproduced immunoglobulin, with IgG being the most common and IgE the rarest and most aggressive. Smoldering multiple myeloma is a ...